Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat and CPX-351 or Palbociclib Pre-Treatment Followed by CPX-351 in R/R AML
NCT05627232Phase 1Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Aug 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tazemetostat and palbociclib in acute myeloid leukemia (AML) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Dose Limiting Toxicities at 1 year. Started Aug 2023; status: recruiting.
02
Drugs
tazemetostatpalbociclib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05627232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627232.